Search Within

Jacqueline Bromberg

  1. "Shanu Modi"
Formats
  1. Meeting Abstract (11)
  2. Journal Article (9)
Groups
  1. Breast Medicine Service (20)
  2. Department of Medicine (20)
  3. GSK Faculty (20)
  4. Solid Tumor Oncology Division (20)
  5. Survivorship Research (20)
  6. Epidemiology and Biostatistics (13)

More Groups

People
  1. Shanu Modi (20)
  2. Chau Dang (11)
  3. Larry Norton (10)
  4. Tiffany Traina (10)
  5. Andrew Seidman (8)
  6. Diana Lake (8)

More People

Years
  1. 2024 (2)
  2. 2023 (1)
  3. 2022 (3)
  4. 2021 (1)
  5. 2020 (4)
  6. 2019 (2)

More Years

Publications
  1. Cancer Research (5)
  2. Journal of Clinical Oncology (4)
  3. Breast Cancer Research and Treatment (2)
  4. International Journal of Radiation Oncology, Biology, Physics (2)
  5. Annals of Oncology (1)
  6. Clinical Breast Cancer (1)

More Publications

Publishers
  1. American Association for Cancer Research (6)
  2. American Society of Clinical Oncology (5)
  3. Elsevier Inc. (3)
  4. Oxford University Press (2)
  5. Springer (2)
  6. Nature Publishing Group (1)

More Publishers

Results (20)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer
    Journal Article

    Wang, D. G.; Barrios, D. M.; Blinder, V. S.; Bromberg, J. F.; Drullinsky, P. R.; Funt, S. A.; Jhaveri, K. L.; Lake, D. E.; Lyons, T.; Modi, S.; more...
    Breast Cancer Research and Treatment (2020)

    Fulltext@MSK | Save
  • A large retrospective analysis of CDK 4/6 inhibitor retreatment in ER+ metastatic breast cancer (MBC)
    Meeting Abstract

    dos Anjos, C. H.; Razavi, P.; Herbert, J.; Colon, J.; Gill, K.; Modi, S.; Bromberg, J.; Dang, C. T.; Liu, D.; Norton, L.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Tumor epichaperome expression using (124)I PU-H71 PET (PU-PET) as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2 negative (HER2-) metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Dunphy, M.; Wang, R.; Comen, E.; Fornier, M.; Moynahan, M. E.; Bromberg, J.; Ma, W.; Patil, S.; Taldone, T.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Safety and tolerability of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer
    Meeting Abstract

    Lyons, T.; Gucalp, A.; Arumov, A.; Patil, S.; Edelweiss, M.; Gorsky, M.; Troso-Sandoval, T. A.; Bromberg, J.; Sanford, R. A.; Iyengar, N. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase II study of paclitaxel and dasatinib in metastatic breast cancer
    Journal Article

    Morris, P. G.; Rota, S.; Cadoo, K.; Zamora, S.; Patil, S.; D'Andrea, G.; Gilewski, T.; Bromberg, J.; Dang, C.; Dickler, M.; more...
    Clinical Breast Cancer (2018)

    Fulltext@MSK | Save
  • A virtual consult service to optimize clinical trial participation in patients with metastatic breast cancer
    Meeting Abstract

    Cadoo, K. A.; Shah, P. D.; Charen, A. S.; Bromberg, J.; Comen, E. A.; D'Andrea, G.; Dang, C. T.; Gilewski, T.; Gucalp, A.; Lake, D.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • An exploratory analysis of the role of dasatinib in preventing progression of disease in bone in patients with metastatic breast cancer
    Meeting Abstract

    Cadoo, K. A.; Morris, P. G.; Lake, D. E.; D'Andrea, G. M.; Dickler, M. N.; Gilewski, T. A.; Dang, C. T.; McArthur, H. L.; Bromberg, J. F.; Goldfarb, S. B.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer
    Journal Article

    Fornier, M. N.; Morris, P. G.; Abbruzzi, A.; D'Andrea, G.; Gilewski, T.; Bromberg, J.; Dang, C.; Dickler, M.; Modi, S.; Seidman, A. D.; more...
    Annals of Oncology (2011)

    Fulltext@MSK | Save
  • A phase I-II trial of dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC)
    Meeting Abstract

    Morris, P. G.; Abbruzzi, A.; D'Andrea, G.; Gilewski, T.; Lake, D.; Bromberg, J.; Dang, C.; Dickler, M.; Modi, S.; Seidman, A. D.; more...
    Cancer Research (2010)

    Fulltext@MSK | Save
  • Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: Updated results
    Meeting Abstract

    Dang, C.; Lin, N.; Moy, B.; Come, S.; Lake, D.; Theodoulou, M.; Troso-Sandoval, T.; Dickler, M.; Gorsky, M.; D'Andrea, G.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save